Neurocrine Biosciences (NASDAQ:NBIX) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says

Neurocrine Biosciences (NASDAQ:NBIX) had its target price increased by stock analysts at Royal Bank Of Canada from $195.00 to $198.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Royal Bank Of Canada’s price objective points to a potential upside of 18.30% from the company’s previous close.

Several other equities research analysts also recently weighed in on the company. Wells Fargo & Company increased their price target on Neurocrine Biosciences from $175.00 to $200.00 and gave the stock an “overweight” rating in a report on Friday, July 17th. JPMorgan Chase & Co. upped their price objective on Neurocrine Biosciences from $177.00 to $185.00 and gave the company an “overweight” rating in a research report on Friday, May 8th. The Goldman Sachs Group initiated coverage on Neurocrine Biosciences in a research note on Tuesday, June 2nd. They issued a “buy” rating and a $213.00 target price on the stock. Citigroup lifted their target price on Neurocrine Biosciences from $242.00 to $246.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. Finally, Weiss Ratings raised shares of Neurocrine Biosciences from a “buy (b-)” rating to a “buy (b)” rating in a research note on Tuesday. Two research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $199.50.

Neurocrine Biosciences Stock Performance

NASDAQ NBIX traded down $18.13 during trading on Friday, hitting $167.37. The stock had a trading volume of 3,492,357 shares, compared to its average volume of 1,197,637. Neurocrine Biosciences has a one year low of $122.14 and a one year high of $186.12. The stock has a 50 day simple moving average of $167.61 and a 200 day simple moving average of $146.25. The stock has a market capitalization of $16.83 billion, a price-to-earnings ratio of 25.74, a P/E/G ratio of 0.76 and a beta of 0.39.

Insider Transactions at Neurocrine Biosciences

In other Neurocrine Biosciences news, insider Ingrid Delaet sold 4,367 shares of the company’s stock in a transaction on Friday, July 10th. The stock was sold at an average price of $181.02, for a total value of $790,514.34. Following the completion of the sale, the insider directly owned 16,225 shares in the company, valued at approximately $2,937,049.50. This represents a 21.21% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Darin Lippoldt sold 10,000 shares of the stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $179.60, for a total value of $1,796,000.00. Following the transaction, the insider directly owned 54,729 shares in the company, valued at $9,829,328.40. The trade was a 15.45% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 395,422 shares of company stock valued at $62,448,693. Company insiders own 4.60% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. DJE Kapital AG bought a new position in shares of Neurocrine Biosciences during the fourth quarter valued at approximately $28,000. Geneos Wealth Management Inc. raised its stake in Neurocrine Biosciences by 143.6% in the first quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock worth $25,000 after buying an additional 135 shares in the last quarter. Meeder Asset Management Inc. raised its stake in Neurocrine Biosciences by 651.6% in the fourth quarter. Meeder Asset Management Inc. now owns 233 shares of the company’s stock worth $33,000 after buying an additional 202 shares in the last quarter. Basecamp Wealth Advisors LLC lifted its holdings in Neurocrine Biosciences by 582.9% during the first quarter. Basecamp Wealth Advisors LLC now owns 239 shares of the company’s stock worth $31,000 after buying an additional 204 shares during the period. Finally, Cassaday & Co Wealth Management LLC purchased a new stake in Neurocrine Biosciences during the first quarter worth $33,000. 92.59% of the stock is currently owned by institutional investors.

Key Neurocrine Biosciences News

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Strong second-quarter results: Revenue rose 39% year over year to $959 million, exceeding the roughly $891 million consensus estimate, while adjusted EPS of $2.85 surpassed estimates. INGREZZA sales increased 15% to $716 million, and CRENESSITY and newly acquired VYKAT XR contributed $184 million and $54 million, respectively. Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results
• Positive Sentiment: INGREZZA guidance raised: Neurocrine increased its 2026 INGREZZA net-sales outlook to $2.825 billion-$2.875 billion, supporting continued confidence in its core commercial franchise. The Soleno Therapeutics acquisition also expands the company’s marketed portfolio and pipeline. NBIX Q2 Earnings Call Highlights
• Positive Sentiment: Analyst support strengthened: TD Cowen, Guggenheim, Cantor Fitzgerald, Piper Sandler, Stifel, Needham and Morgan Stanley all raised their price targets. Targets now range from $196 to $222, while William Blair reiterated a Buy rating based on execution, pipeline expansion and potential multi-billion-dollar peak sales. William Blair Buy Rating
• Neutral Sentiment: Market expectations remain elevated: The earnings call highlighted growth from INGREZZA, CRENESSITY, VYKAT XR and pipeline programs, but investors are assessing whether the expanded portfolio can generate additional upside beyond current estimates. Neurocrine Q2 2026 Earnings Call Transcript
• Negative Sentiment: Guidance reaction disappointed investors: Despite the INGREZZA increase, the broader outlook was viewed as offering limited room for additional upside. Traders appeared to want a larger revenue beat or more substantial guidance increase, prompting a sharp, high-volume selloff. Neurocrine Q2 Results and Outlook Analysis
• Negative Sentiment: Insider selling adds a cautionary signal: Director Leslie Norwalk sold 1,250 shares under a pre-arranged Rule 10b5-1 plan. Broader data shows company insiders recorded numerous sales and no open-market purchases over the past six months, though such transactions may be scheduled and do not necessarily indicate deteriorating fundamentals. SEC Insider Transaction Filing

About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.